Effect of venlafaxine on the pharmacokinetics of risperidone

Journal of Clinical Pharmacology

Volumn 39, Issue 3, 1999, Pages 297-309

  Amchin, Jess ^a   Zarycranski, William ^a   Taylor, Karen P ^a   Albano, Dominick ^a   Klockowski, Patricia M ^b  

^a WYETH AYERST RESEARCH   (United States)

^b Oneida Research Services Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEBRISOQUINE 4 HYDROXYLASE; DRUG METABOLITE; PALIPERIDONE; RISPERIDONE; VENLAFAXINE;

ADULT; ANXIETY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DISTRIBUTION VOLUME; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG SAFETY; DRUG URINE LEVEL; FEMALE; HUMAN; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PSYCHOMOTOR PERFORMANCE; STEADY STATE; URINARY EXCRETION; WITHDRAWAL SYNDROME;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; ANXIETY; AREA UNDER CURVE; CYCLOHEXANOLS; EXPLORATORY BEHAVIOR; FEMALE; HUMANS; ISOXAZOLES; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PSYCHOMOTOR PERFORMANCE; PYRIMIDINES; RISPERIDONE;

EID: 0032979763     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Richelson E: Pharmacology of antidepressants: characteristics of the ideal drug. Mayo Clin Proc 1994;69:1069-1081.
2. Scott MA, Shelton PS, Gattis W: Therapeutic options for treating major depression and the role of venlafaxine. Pharmacotherapy 1996;16:352-365.
3. Cohen LJ: Rational drug use in the treatment of depression. Pharmacotherapy 1997;17:45-61.
4. Montgomery SA: Venlafaxine: a new dimension in antidepressant pharmacotherapy. J Clin Psychiatry 1993;54:119-126.
5. Klamerus KJ, Maloney D, Rudolph RL, Sisenwine SR Jusko WJ, Chiang ST: Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-metabolite. J Clin Pharmacol 1992;32:716-724.
6. Muth EA, Moyer JA, Haskins JT, Andree TH, Husbands GEM: Biochemical, neurophysiological and behavioral effects of Wy-45,233, its enantiomers, and other identified metabolites of the antidepressant venlafaxine. Drug Dev Res 1991;23:191-199.
7. Muth EA, Moyer JA, Andre;e TH: A pharmacological profile of Wy-45,233, the major metabolite in humans of the novel bicyclic antidepressant candidate, Wy-45,030 (abstract 130.4). Proceedings of the 16th Annual Meeting of the Society for Neuroscience 1986;12:473.
8. Troy SM, Parker VD, Fruncillo RJ, Chiang ST: The pharmacokinetics of venlafaxine when given in a twice-daily regimen. J Clin Pharmacol 1995;35:404-409.
9. Troy SM, Schultz RW, Parker VD, Chiang ST, Blum RA: The effect of renal disease on the disposition of venlafaxine. Clin Pharmacol Ther 1994;56:14-21.
10. Holliday SM, Benfield P: Venlafaxine: a review of its pharmacology and therapeutic potential in depression. Drugs 1995;49:280-294.
11. 14C-venlafaxine in mouse, rat, dog, rhesus monkey and man. Xenobiotica 1993;23:349-359.
12. Otton SV, Ball SE, Cheung SW, Inaba T, Rudolph RL, Sellers EM: Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol 1996;41:149-156.
13. Fogelman S, Schmider J, Greenblatt DJ, Shader RI: Metabolism of venlafaxine: the role of P450 isoforms (abstract). J Clin Pharmacol 1995;35:936.
14. Ball SE, Ahern D, Scatina J, Kao J: Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism: comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. Br J Clin Pharmacol 1997;43:619-626.
15. Ereshefsky L: Drug-drug interactions involving antidepressants: focus on venlafaxine. J Clin Psychopharmacol 1996;16(Suppl. 2):37S-53S.
16. Amchin JD, Ereshefsky L, Zarycranski WM: Effect of venlafaxine versus fluoxetine on the metabolism of dextromethorphan, a CYP2D6 marker. Presented at the annual meeting of the American Psychiatric Association, May 1996, New York.
17. Amchin J, Zarycranski W, Taylor KP, Albano D, Klockowski PM: Effect of venlafaxine on CYP1A2-dependent pharmacokinetics and metabolism of caffeine. J Clin Pharmacol 1999;39:252-259.
18. Amchin J, Zarycranski W, Taylor KP, Albano D, Klockowski PM: Effect of venlafaxine on the pharmacokinetics of terfenadine. Psychopharmacol Bull 1998;34(3):383-389.
19. Amchin J, Zarycranski W, Taylor KP, Albano D, Klockowski PM: Effect of venlafaxine on the pharmacokinetics of alprazolam. Psychopharmacol Bull 1998;34(2):211-219.
20. Troy SM, Lucki I, Peirgies AA, Parker VD, Klockowski PM, Chiang ST: Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and diazepam. J Clin Pharmacol 1995;35:410-419.
21. 2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. Psychopharmacol 1995;119:345-348.
22. 2 receptors. Int Clin Psychopharmacol 1995;10:19-30.
23. Mesotten F, Suy E, Pietquin M, Burton P, Heyler S, Gelders Y: Therapeutic effects and safety of increasing dose of risperidone (R64766) in psychotic patients. Psychopharmacol 1989;99:445-449.
24. Gelders YG, Heylen SLE, Vanden Bussche G, Reyntjens AJM, Janssen PAJ: Pilot clinical investigation of risperidone in the treatment of psychotic patients. Pharmacopsychiatry 1990;23:206-211.
25. Mertens C: Long-term treatment of chronic schizophrenic patients with risperidone. Schizophr Res 1990;3:48.
26. Livingston MG: Risperidone. Lancet 1994;343:457-460.
27. Grant S, Fitton A: Risperidone: a review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs 1994;48:253-273.
28. Heykants J, Huang M-L, Mannens G, Meuldermans W, Snoeck E, Van Beijsterveldt L, Van Peer A, Woestenborghs R: The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry 1994;55(Suppl. 5):13-17.
29. Huang M-L, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AAI, Zylicz Z, Visscher HW, Jonkman JHG: Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 1993;54:257-268.
30. Mannens G, Meuldermans W, Snoeck E, Heykants J: Plasma protein binding of risperidone and its distribution in blood. Psychopharmacology Berl 1994;114:566-572.
31. Mannens G, Huang M-L, Meuldermans W, Hendrickx J, Woestenborghs R, Heykants J: Absorption, metabolism, and excretion of risperidone in humans. Drug Metab Dispos 1993;21:1134-1141.
32. Koymans L, Vermeulen MPE, van Acker SABE, te Koppele JM, Heykants JJP, Lavrijsen K, Meuldermans W, Donné-Op den Kelder GM: A predictive model for substrates of cytochrome P450-debrisoquine (2D6). Chem Res Toxicol 1992;5:211-219.
33. Drug Facts and Comparisons: Facts and Comparisons. 52nd ed. St. Louis, MO: Drug Facts and Comparisons, 1998:1715-1726.
34. Brosen K, Gram LF: Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 1989;36:537-547.
35. Wechsler D: Manual for the Wechsler Adult Intelligence Scale - Revised. New York: The Psychological Corporation, 1981.
36. Risperdal®. In, Physicians' Desk Reference. 51st ed. Montvale, NJ: Medical Economics Company, 1997;1348-1352.
37. Guy W: Abnormal Involuntary Movement Scale. In, ECDEU Assessment Manual for Psychopharmacology. DHEW Pub. No. 76-338. Bethesda, MD: National Institute of Mental Health, 1976.
38. Jusko WJ: Guidelines for collection and analysis of pharmacokinetic data. In, Evans WE, Schentag JJ, Jusko WJ (eds.): Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. 3rd ed. Vancouver: Applied Therapeutics, 1992.
39. SAS Institute, Inc.: SAS/STAT User's Guide. Version 6, 4th ed., vols. 1 and 2. Cary, NC: SAS Institute, Inc., 1990.
40. Steel RGD, Torrie JH: Principles and Procedures of Statistics. New York: McGraw-Hill, 1980.
41. Chow SC, Liu JP. Recent statistical developments in bioequivalence trials: a review of the FDA guidance. Drug Inf J 1994;28:851-964.